Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEXG vs PDXG in Locally Advanced or Metastatic Pancreatic Adenocarcinoma
2005-002586-36Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cisplatin, docetaxel, gemcitabine, epirubicin and capecitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Started Jul 2005; status: completed.
02
Drugs
cisplatindocetaxelgemcitabineepirubicincapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-002586-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002586-36.